RAPPRapport Therapeutics, Inc.
$30.68+16% 1Y
$30.68
$24.3752 weeks$52.44
RAPP as reported
- Net income
- −$137M
Net income · +55% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$97M
Free cash flow · +26% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.03
EPS · +48% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$137M | +55% | Q2 2026 |
| EPS | −$3.03 | +48% | Q2 2026 |
| ROE | −24% | n/a | Q2 2026 |
| ROA | −23% | n/a | Q2 2026 |
| Free cash flow | −$97M | +26% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Rapport Therapeutics, Inc. (RAPP) · Revenue and profitRevenue and profitRapport Therapeutics, Inc. (RAPP)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
Biotechnology
The closest names by size in the same industry